Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Design, synthesis, and biological evaluation of novel 1,2-diaryl-4-substituted-benzylidene-5(4H)-imidazolone derivatives as cytotoxic agents and COX-2/LOX inhibitors

PF. Lamie, JN. Philoppes, L. Rárová,

. 2018 ; 351 (3-4) : e1700311. [pub] 20180205

Language English Country Germany

Document type Journal Article

A new series of 1,2-diaryl-4-substituted-benzylidene-5(4H)-imidazolone derivatives 4a-l was synthesized. Their structures were confirmed by different spectroscopic techniques (IR, 1 H NMR, DEPT-Q NMR, and mass spectroscopy) and elemental analyses. Their cytotoxic activities in vitro were evaluated against breast, ovarian, and liver cancer cell lines and also normal human skin fibroblasts. Cyclooxygenase (COX)-1, COX-2 and lipoxygenase (LOX) inhibitory activities were measured. The synthesized compounds showed selectivity toward COX-2 rather than COX-1, and the IC50 values (0.25-1.7 µM) were lower than that of indomethacin (IC50  = 9.47 µM) and somewhat higher than that of celecoxib (IC50  = 0.071 µM). The selectivity index for COX-2 of the oxazole derivative 4e (SI = 3.67) was nearly equal to that of celecoxib (SI = 3.66). For the LOX inhibitory activity, the new compounds showed IC50 values of 0.02-74.03 µM, while the IC50 of the reference zileuton was 0.83 µM. The most active compound 4c (4-chlorobenzoxazole derivative) was found to have dual COX-2/LOX activity. All the synthesized compounds were docked inside the active site of the COX-2 and LOX enzymes. They linked to COX-2 through the N atom of the azole scaffold, while CO of the oxazolone moiety was responsible for the binding to amino acids inside the LOX active site.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19000940
003      
CZ-PrNML
005      
20190114092958.0
007      
ta
008      
190107s2018 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ardp.201700311 $2 doi
035    __
$a (PubMed)29400411
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Lamie, Phoebe F $u Faculty of Pharmacy, Department of Pharmaceutical Organic Chemistry, Beni-Suef University, Beni-Suef, Egypt.
245    10
$a Design, synthesis, and biological evaluation of novel 1,2-diaryl-4-substituted-benzylidene-5(4H)-imidazolone derivatives as cytotoxic agents and COX-2/LOX inhibitors / $c PF. Lamie, JN. Philoppes, L. Rárová,
520    9_
$a A new series of 1,2-diaryl-4-substituted-benzylidene-5(4H)-imidazolone derivatives 4a-l was synthesized. Their structures were confirmed by different spectroscopic techniques (IR, 1 H NMR, DEPT-Q NMR, and mass spectroscopy) and elemental analyses. Their cytotoxic activities in vitro were evaluated against breast, ovarian, and liver cancer cell lines and also normal human skin fibroblasts. Cyclooxygenase (COX)-1, COX-2 and lipoxygenase (LOX) inhibitory activities were measured. The synthesized compounds showed selectivity toward COX-2 rather than COX-1, and the IC50 values (0.25-1.7 µM) were lower than that of indomethacin (IC50  = 9.47 µM) and somewhat higher than that of celecoxib (IC50  = 0.071 µM). The selectivity index for COX-2 of the oxazole derivative 4e (SI = 3.67) was nearly equal to that of celecoxib (SI = 3.66). For the LOX inhibitory activity, the new compounds showed IC50 values of 0.02-74.03 µM, while the IC50 of the reference zileuton was 0.83 µM. The most active compound 4c (4-chlorobenzoxazole derivative) was found to have dual COX-2/LOX activity. All the synthesized compounds were docked inside the active site of the COX-2 and LOX enzymes. They linked to COX-2 through the N atom of the azole scaffold, while CO of the oxazolone moiety was responsible for the binding to amino acids inside the LOX active site.
650    _2
$a antiflogistika nesteroidní $x chemická syntéza $x chemie $x farmakologie $7 D000894
650    _2
$a arachidonát-5-lipoxygenasa $x metabolismus $7 D001094
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a kultivované buňky $7 D002478
650    _2
$a cyklooxygenasa 2 $x metabolismus $7 D051546
650    _2
$a inhibitory cyklooxygenasy 2 $x chemická syntéza $x chemie $x farmakologie $7 D052246
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    12
$a racionální návrh léčiv $7 D015195
650    _2
$a lidé $7 D006801
650    _2
$a imidazoly $x chemická syntéza $x chemie $x farmakologie $7 D007093
650    _2
$a inhibitory lipoxygenas $x chemická syntéza $x chemie $x farmakologie $7 D016859
650    _2
$a simulace molekulového dockingu $7 D062105
650    _2
$a molekulární struktura $7 D015394
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
655    _2
$a časopisecké články $7 D016428
700    1_
$a Philoppes, John N $u Faculty of Pharmacy, Department of Pharmaceutical Organic Chemistry, Beni-Suef University, Beni-Suef, Egypt.
700    1_
$a Rárová, Lucie $u Department of Chemical Biology and Genetics, Centre of the Region Haná for Biotechnological and Agricultural Research, Institute of Experimental Botany ASCR and Palacký University, Olomouc, Czech Republic.
773    0_
$w MED00000507 $t Archiv der Pharmazie $x 1521-4184 $g Roč. 351, č. 3-4 (2018), s. e1700311
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29400411 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190114093207 $b ABA008
999    __
$a ok $b bmc $g 1364909 $s 1039063
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 351 $c 3-4 $d e1700311 $e 20180205 $i 1521-4184 $m Archiv der Pharmazie $n Arch Pharm $x MED00000507
LZP    __
$a Pubmed-20190107

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...